Product Description
anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus); V920/BPSC-1001 is an experimental Ebola vaccine candidate demonstrating protection against Ebola virus in animal experiments. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02269423)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hemorrhagic Fever, Ebola|Hemorrhagic Fevers, Viral
Phase 2: Hemorrhagic Fever, Ebola
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02314923 |
V920-004 | P1 |
Completed |
Hemorrhagic Fever, Ebola |
2016-06-23 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT02283099 |
rVSVΔG-ZEBOV-GP | P1 |
Completed |
Hemorrhagic Fevers, Viral|Hemorrhagic Fever, Ebola |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT02269423 |
V920-001 | P1 |
Completed |
Hemorrhagic Fever, Ebola |
2015-08-25 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT02374385 |
VSVΔG-ZEBOV | P1 |
Completed |
Hemorrhagic Fever, Ebola |
2015-03-01 |
2019-03-20 |
Treatments |
|
NCT02287480 |
VSV-ZEBOV | P2 |
Completed |
Hemorrhagic Fever, Ebola |
2015-04-01 |
2019-03-20 |
||
NCT02378753 |
STRIVE | P3 |
Completed |
Hemorrhagic Fevers, Viral|Hemorrhagic Fever, Ebola |
2016-11-08 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|